

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 30457.0013USWO	Application Number: 10/550,165
	Applicant: Paul Savage et al.	
	Filing Date: July 21, 2006	Group Art Unit: 1623

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2005/0222048	10/06/2005	Tsuji et al.			
	2006/0211856	09/21/2006	Tsuji et al.			
	2005/0192248	09/01/2005	Tsuji et al.			
	2004/0166554	08/26/2004	Chamoles			
	2009/0047299	02/19/2009	Savage			
	2006/0019246	01/26/2006	Tsuji et al.			
	5,242,800	09/07/1993	Jimenez et al.			
	5,785,975	07/28/1998	Parikh			
	5,958,426	09/28/1999	Moreau et al.			
	6,417,167	07/09/2002	Maruyama et al.			
	6,610,835	08/26/2003	Liotta et al.			
	6,635,622	10/21/2003	Tomiyama et al.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0988860	03/29/2000	EP				
	EP 1016409	07/05/2000	EP				
	WO 99/33475	07/08/1999	PCT				
	WO 03/009812	02/06/2003	PCT				
	WO 03/105769	12/24/2003	PCT				
	WO 05/102049	11/03/2005	PCT				
	WO 06/029010	03/16/2006	PCT				
	WO 07/050668	05/03/2007	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BEAUDOIN, L. et al., "NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells," Immunity (2002) 17:725-736
	BENDELAC, A. et al., "Autoreactivity by design: innate B and T lymphocytes," Natur. Rev. Immunol. (2001)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 30457.0013USWO	Application Number: 10/550,165
	Applicant: Paul Savage et al.	
	Filing Date: July 21, 2006	Group Art Unit: 1623

		1:177-186
		BENDELAC, A. et al., "The biology of NKT cells," <i>Ann. Rev. Immunol.</i> (2007) 25:297-336
		BENDELAC, A., "Nondeletional pathways for the development of autoreactive thymocytes," <i>Nat. Immunol.</i> (2004) 5:557-558
		BROSSAY, L. et al., "Cutting edge: structural requirements for galactosylceramide recognition by CD1-restricted NK T cells," <i>J. Immunol.</i> (1998) 161(10):5124-5128
		DAOUDI, J.-M. et al., "New bicyclam-galcer analogue conjugates: synthesis and in vitro anti-HIV activity," <i>Biorg. Med. Chem. Lett.</i> (2004) 14:495-498
		DE LIBERO, G. et al., "Self glycosphingolipids: new antigens recognized by autoreactive T lymphocytes," <i>News Physiol. Sci.</i> (2003) 18:71-76
		European Office Action for Application No. 05810863.0 dated April 2, 2008 (4 pages)
		FISCHER, K. et al., "Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells," <i>Proc. Natl. Acad. Sci. USA</i> (2004) 101:10685-10690
		GOODMAN & GILMAN's The Pharmacological Basis of Therapeutics, Tenth Edition, Hardman and Limbird, editors, The McGraw-Hill Companies, Inc., New York, (2001) 54-56
		GUMPERZ, J.E. et al., "Murine CD1d-restricted T cell recognition of cellular lipids," <i>Immunity</i> (2000) 12:211-221
		GUPTA, R.K. et al., "Adjuvants - a balance between toxicity and adjuvanticity," <i>Vaccine</i> (1993) 11(3):293-306
		HONEY, K. et al., "Thymocyte expression of cathepsin L is essential for NKT cell development," <i>Nat. Immunol.</i> (2002) 3:1069-1074
		International Search Report and Written Opinion for Application No. PCT/US2005/031407 (13 pages)
		ISLAM, I. et al., "Synthesis and antiviral activity of (2-((4-(3-((1-methylethyl)amino)-2-pyridyl)-1-piperazinyl)carbonyl)-1H-indo 1-5-yl) (BHAP) acylspongine HIV reverse transcriptase inhibitors," <i>Biorg. Chem.</i> (1995) 23(4):499-511
		KITAMURA, H. et al., "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells," <i>J. Exp. Med.</i> (1999) 189:1121-1127
		PARK, S.-H. et al., "Tissue-specific recognition of mouse CD1 molecules," <i>J. Immunol.</i> (1998) 160:3128-3134
		PRIGOZY, T.I. et al., "Glycolipid antigen processing for presentation by CD1d molecules," <i>Science</i> (2001) 291:664-667
		SMYTH, M.J. et al., "NKT cells - conductors of tumor immunity?" <i>Curr. Opin. Immunol.</i> (2002) 14(2):165-171
		SMYTH, M.J. et al., "NKT cells and tumor immunity - a double-edged sword," <i>Nature Immunology</i> (2001) 1:459-460
		STANIC A.K. et al., "Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by Beta-D-glucosylceramide synthase deficiency," <i>Proc. Natl. Acad. Sci. USA</i> (2003) 100:1849-1854

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 30457.0013USWO	Application Number: 10/550,165
	Applicant: Paul Savage et al.	
	Filing Date: July 21, 2006	Group Art Unit: 1623

		United States Office Action for Application No. 11/218,906 dated 11/10/2008 (8 pages)
		United States Office Action for Application No. 11/771,128 dated October 29, 2008 (14 pages)
		VAN DER VLIET, H.J.I. et al., "Effects of α -galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human $V\alpha 24+ V\beta 11+T$ cells," Immunology (1999) 98:557-563
		VANDOMMELEN, S.L.H. et al., "Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells," J. Virology (2003) 77(3):1877-1884
		WINAU, F. et al., "Saposin C is required for lipid presentation by human CD1b," Nat. Immunol. (2004) 5:169-174
		WU, D.Y. et al., "Cross-presentation of disialoganglioside GD3 to natural killer T cells," J. Exp. Med. (2003) 198:173-181
		XIA, C. et al., "Thio-isoglobotrihexosylceramide, an Agonist for activating invariant natural killer T cells," Org. Lett. (2006) 8(24):5493-5496
		ZAJONC, D.M. et al., "Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity," J. Exp. Med. (2005) 202(11):1517-1526
		ZHOU, D. et al., "Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins," Science (2004) 303:523-527
		ZHOU, D., "The immunological function of iGb3," Curr. Prot. Pept. Sci. (2006) 7:325-333

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	